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Abstract: The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly growing, affecting 25%
of the world population. Non-alcoholic steatohepatitis (NASH) is the most severe form of NAFLD and
affects 1.5% to 6.5% of the world population. Its rising incidence will make end-stage liver disease (ESLD)
due to NASH the number one indication for liver transplantation (LT) in the next 10 to 20 years, overtaking
Hepatitis C. Patients with NASH also have a high prevalence of associated comorbidities such as type 2
diabetes, obesity, metabolic syndrome, cardiovascular disease, and chronic kidney disease (CKD), which must
be adequately managed during the peritransplant period for optimal post-transplant outcomes. The focus of
this review article is to provide a comprehensive overview of the unique challenges these patients present in
the peritransplant period, which comprises the pre-transplant, intraoperative, and immediate postoperative
periods.
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Nonalcoholic steatohepatitis (NASH) is currently the
second leading cause for liver transplantation (LT) waitlist
registration/liver transplantation overall, and in females, the
leading cause. It is projected that NASH will likely rise to
become the leading indication for LT in males as well (1).
According to the United Network for Organ Sharing and
Organ Procurement and Transplantation Network data,
there was a 162% increase in LT secondary to NASH
from 2003 to 2014 (2). NASH cirrhosis is the most rapidly
growing indication for ACLF-related hospitalization and
use of hospital resources (3). ACLF increased by 24%
between 2006 and 2014 with a 63% increase in nonalcoholic
steatohepatitis (NASH) cirrhosis (3.5% to 5.7%); a 28%
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increase in patients with alcoholic cirrhosis (5.6% to 7.2%);
a 25% increase in patients with other etiologies (5.2%
to 6.5%); and no significant change in patients with viral
hepatitis (4.0% to 4.1%) (3). NASH as a cause of LT related
to hepatocellular carcinoma (HCC), increased from 8.3%
in 2002 to 10.3% in 2007 to 13.5% in 2012. The number
of patients undergoing LT for HCC secondary to NASH
increased by nearly 4-fold from 2002–2012 (4). NASH
patients requiring LT were older and waitlist mortality
was higher compared to patients with other etiologies of
chronic liver disease (5). Dulai et al. did a systematic review
and meta-analysis of 5 studies. Cumulative incidence of
death within 3 years of listing for LT was 29% in NASH (6).
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Table 1 Summary of early post-LT mortality across various studies in NASH patients vs. non-NASH patients
Study

Year

Haldar et al. (10)

NASH survival (%)

Non-NASH survival (%)

Patients (N)

30-day

90-day

1 year

Patients (N)

30-day

90-day

1 year

2019

1,667

–

–

84.1

48,206

–

–

86.3

Agopian et al. (11)

2012

144

–

90

84

1,150

–

93

81

Kennedy et al. (12)

2012

129

–

–

90

775

–

–

92

Vanwagner et al.* (13)

2012

115

–

–

81.3

127

–

–

88.1

Afzali et al.** (14)

2011

1,810

–

–

87.6

–

–

–

–

Barritt et al. (15)

2011

21

80.9

–

76.2

97

97

–

83.5

Charlton et al. (16)

2011

1,959

–

–

84

33,971

–

–

87

Yalamanchili et al. (17)***

2010

18

–

–

85.6

1,795

–

–

86.3

Malik et al. (18)

2009

98

95.9

–

78.6

686

95.8

–

84.8

Bhagat et al. (19)

2009

71

–

–

82

83

–

–

92

*, alcohol-induced liver disease – NASH patients more likely to die from adverse CV event; predicted by prolonged QT interval; **, authors
concluded that NASH patients more likely to die from CV complications. Risk factors were old age and obesity; ***, authors concluded
that NASH patients are more likely to die from CV disease.

Factors such as poor performance status, encephalopathy,
diabetes, high MELD score, Hispanic race, older age, and
a low serum albumin were the main causes of death in
patients with NASH who were on the waitlist for LT (7).
NASH is considered as the hepatic manifestation of
metabolic syndrome, and as such, the constellation of
comorbidities such as diabetes, hypertension, dyslipidemia,
and obesity are significantly common in these patients (8).
In addition, complications related to these comorbidities
such as chronic kidney disease (CKD) and coronary artery
disease (CAD) are quite common in NASH patients,
and their increased prevalence puts significant clinical
challenges in the management of NASH patients on the LT
wait-list and during the peritransplant period (9). In this
review, we have described these complex challenges in the
management of NASH patients with end stage liver disease
and attempted to guide clinicians to best manage and
prevent future complications with early interventions.
Risk factors affecting graft and patient survival
in NASH
Recent meta-analysis of 9 studies showed survival of
patients at 1, 3, and 5 years after liver transplantation was
similar to other chronic liver disease. Studies that have
compared mortality following LT in patients with NASH
to post-LT patients with Non-NASH cirrhosis (10-19)
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are summarized in Table 1. There are unique challenges
faced by patients with NASH undergoing LT, a summary
of those as well as guideline-based management in the
peri-transplant period are summarized in Table 2 (20-38).
Patients with NASH are more likely to die from
cardiovascular complications or sepsis (39). While some
studies showed NASH did not affect graft survival (19),
other studies have shown a negative impact of NASH on graft
survival, primarily due to underlying metabolic factors (15).
Factors including age >60 years, BMI ≥30 kg/m 2 ,
pretransplant HTN, and T2DM, have led to increased
30-day and 1-year mortality (18). Both obese patients with
BMI more than 40 and underweight patients with BMI
less than 18 are associated with increased risk of infectious
complications and death (40). Beckman et al. did a metaanalysis of 37 studies and proved the negative effect of
obesity on LT outcomes. Patients with BMI >30 had worse
patient survival (72.6% and 69.8%) and graft survival
(75.8% and 85.4%) than those with normal weight (41).
Obesity and type 2 diabetes concomitantly increased
30-day postoperative event rate, length of hospital stay and
decreased graft survival (42). Usually post-transplant diabetes
can develop within 6–12 months after surgery and these
patients have increased rejection and worse survival (43).
Close management of the components of metabolic
syndrome is crucial to long-term survival and may combat
the adverse effects of immunosuppression, improving
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Table 2 Unique challenges in peri-transplant period for NASH patients with reference to guidelines
Peri transplant
challenge

Impact on morbidity and mortality

Guideline recommendations

Obesity and
metabolic
syndrome

 Increased primary graft nonfunction, and decreased
survival at 30 days, 1-, and 2-year follow-up in
morbidly obese patients undergoing LT (20)

 AASLD considers morbid obesity [body mass index
(BMI) ≥40 kg/m2] as a relative contraindication for liver
transplantation, since these patients seem to be exposed
to a higher risk of post-transplant complications and
mortality (21)

 Increased mortality risk and higher early postoperative  EASL practice guidelines state that a multidisciplinary
complications, mainly due to cardiopulmonary
team should carefully evaluate patients with a BMI >35
complications in post-LT period (22)
before being included in the waiting list (23)
Diabetes

 Pretransplant diabetes is associated with inferior
post-operative outcomes and increased resource
utilization after liver transplantation (24)

 Not enough of evidence to make recommendations for
management of diabetes in early stages of cirrhosis (25)

Intraoperative
hyperglycemia

 Hyperglycemia increases risk of postoperative
infection and mortality (26)

 Not available

Cardiovascular
disease

 Mortality due to coronary artery disease and
cerebrovascular disease is highest among patients
with NASH within first year of liver transplantation
compared to other liver disease etiologies (27)

 ACC/AHA recommends coronary revascularization prior to
liver transplant in candidates with severe CAD; bare metal
stenting is the chosen approach

 Occurrence of a cardiovascular event perioperatively
associated with increased overall mortality (28)

 In patients with nonobstructive CAD, medical management
with beta blockers and statins is suggested
 AASLD recommends NASH patients should careful
evaluation of identifying CVD during the transplant
evaluation process (29). See Figure 1 for an algorithm

Acute kidney
injury

 Post-LT acute kidney injury associated with increased  Not available
mortality and graft failure (30)

Chronic kidney
disease

 In patients with NASH, CKD was associated with
increased overall mortality (31)

 Not available

 Pre-transplant renal impairment along with diabetes
is a predictor for increased post-liver transplant
cardiovascular disease mortality (32)
Sarcopenia

 Sarcopenia increases risk for delisting and death (33)
 Sarcopenia is associated with post-LT infectious
complications and sepsis-related mortality (35)

Portal vein
thrombosis

 PVT decreases post-LT graft and patient survival (36)

 ESPEN recommends a target intake of 35–40 kcal/kg/day
and 1.2–1.5 g/kg/day of protein (34)

 Not available

 No impact on waitlist mortality (37)
 Independent risk factor for 90-day mortality (38)

PVT, portal venous thrombosis.

graft survival and decreasing rates of sepsis. Patients with
NASH are known to have poor performance status, which
has been linked to decreased graft survival and overall
patient 5-year survival rates when compared with the
other groups after adjusting for demographic and disease
complication factors (44). African American donors are
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shown to have an increased risk of liver graft loss by 21.5%.
When both donor and recipient were African American,
graft loss increased by 36.6% (45). Optimization of obesity,
hypertension, hyperlipidemia, pre-transplant cardiovascular
disease, and smoking status are important in decreasing
graft loss in NASH patients.
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Potential LT candidate

Clinical Assessment,
History, Examination, EKG

≥3 CAD risk factors* or
BMI ≥35 or presence of
Diabetes with 1 additional
risk factor for CAD

Transthoracic
Echocardiogram

(−)
Low-risk

DSE Test

(+)

If abnormal DSE

High-risk

Proceed with Coronary
angiogram +/–
resvascularization
IF Angiogram NORMAL,
then proceed with Listing

Figure 1 An algorithm for evaluating for cardiovascular risk in patients undergoing liver transplantation. All patients undergoing liver
transplantation require a transthoracic echocardiogram, which can help determine the next steps in management. *, CAD risk factors: age
(>45 years in males, >55 in females), Hx of smoking, hypertension, dyslipidemia, T2 DM, family hx of CAD, known hx of CAD). CAD,
coronary artery disease; DSE, Dobutamine Stress Echocardiogram.

Donor and allocation issues
Older age, higher BMI, increased prevalence of
diabetes and donation after cardiac death (DCD) are
leading cause for liver nonuse (46). Miyaaki et al. noted
that younger age of recipients and donor steatosis
are risk factors for post-LT NASH (47). Zhang et al.
conducted meta-analysis of 19 publications to estimate the
effect of steatotic livers after LT and noted primary non
function rate and early dysfunction rate was higher when
moderate and severe steatotic liver donors were used. But
graft survival rate and patient survival rate did not differ
between steatotic and non steatotic liver donors (27).
Recipients receiving liver with macrosteatosis are at
increased risk of post reperfusion syndrome, renal
dysfunction requiring continuous renal replacement
therapy (RRT) following LT, and cardiac arrest compared
to donors without steatosis (48). Steatotic grafts with >60%
fat are generally not transplanted, while those with 30–
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60% fat when transplanted have been associated with poor
results and should be considered as donors in the absence
of other risk factors (49). However, Wong et al. assessed
patients who received severely steatotic liver donors and
proved even severely steatotic liver donors from low risk
donors can be safely used (50). Non-enhanced computed
tomography and contrast-enhanced CT attenuation
measurements of liver is useful in evaluating steatosis in
donor candidates with moderate to severe steatosis (51).
Magnetic resonance proton density fat fraction (MRPDFF) has good negative predictive value for diagnosing
donor hepatic steatosis >10% in living donor LTs (52).
Zheng et al. did meta-analysis of 8 studies and noted MR
imaging and MR spectroscopy has high sensitivity and high
specificity for diagnosing hepatic steatosis >10% to >30%
in living liver donors (53).
Preoperative and selective intraoperative liver biopsies
are proven to be specific compared to imaging studies
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for assessing donor steatosis and can be considered in
patients with abnormal imaging studies to evaluate the liver
steatosis on donors (54). Pharmacological enhancement of
intracellular lipid metabolism and defatting done during
normothermic machine perfusion decreased steatosis in
donor livers and reduced the inflammatory cytokines in the
perfusate (55). Strategies such as shortened ischemia time,
ischemic and pharmacological preconditioning of liver
grafts, and the use of machine-based liver perfusion systems
are used to optimize fatty liver grafts, which is necessary for
deceased liver donors. In patients undergoing living donor
LT, Bezafibrate (400 mg/day) for 2–8 weeks in the donors
have reduced risk of liver injury in live steatotic grafts (31).
Factors affecting peritransplant outcomes in
NASH patients
Obesity and metabolic syndrome
Obesity increases the risk of clinical decompensation in
cirrhosis, possibly by increasing portal pressure. Sixteen
weeks of diet and moderate exercise were safe and reduced
body weight and portal pressure in overweight and obese
patients with cirrhosis and portal hypertension (56). The
impact of bariatric surgery on LT candidates was assessed by
a few studies. Idriss et al. studied 78 adults who underwent
liver transplant evaluation after bariatric surgery and noticed
that when compared with controls without a history of
bariatric surgery, patients with a history of bariatric surgery
were more likely to be listed for LT, but a higher rate of
delisting or death on the waiting list was noticed in patients
with bariatric surgery secondary to malnutrition (57).
Sleeve gastrectomy is shown to be a possibly safe
alternative that can reduce the metabolic complications
in the peritransplant period before and after LT while
also decreasing the risk of malnutrition during LT and
eliminating the risk of malabsorption of immunosuppressive
drugs. Furthermore, sleeve gastrectomy allows for good
endoscopic evaluation of varices and biliary complications
(58,59).
Patients with morbid obesity had an increased length
of stay in the hospital and appeared sick, which required
extensive use of hospital resources (60). Obese patients
are known to have an increase in mortality while on the
waitlist and had decreased post-LT survival. A summary
of studies comparing mortality in obese post-LT
patients to non-obese post-LT patients (20,61-70,71-77)
is summarized in Table 3. Obese patients were less
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likely to get LT compared to nonobese patients because
of excessive post-operative risks (78). With respect
to operative outcomes, patients with Class II obesity
(BMI >35) or higher MELD scores transplanted for NASH
had no difference in operative time, intensive care unit or
hospital length of stay, or perioperative complications when
compared to non-obese patients undergoing LT (63).
Studies examining survival outcomes in obese patients
undergoing LT have shown conflicting results (79,80). Nair
et al. (20) reviewed the UNOS database from 1988 through
1996 and reported increased primary graft nonfunction as
well as decreased survival at 30 days, 1-, and 2-year followup in morbidly obese patients undergoing LT. Despite
these earlier reports, Pelletier et al. (79) demonstrated
that there was a survival benefit from transplantation
not only for obese patients but also for patients at the
extremes of BMI. A recent meta-analysis of 24 studies on
132,162 patients also reported increased mortality risk
and higher early postoperative complications, mainly
due to cardiopulmonary complications in obese patients
after LT compared to the controls (22). Currently, the
American Association for the Study of Liver Disease
(AASLD), in accordance with the American Society of
Transplantation, considers morbid obesity [body mass
index (BMI) ≥40 kg/m2] as a relative contraindication for
LT, since these patients seem to be exposed to a higher
risk of post‐transplant complications and mortality (21).
The European Association for the Study of the Liver
(EASL) also highlights increased postoperative infections
and increased hospital and/or intensive care unit length
of stay in obese patients and the EASL practice guidelines
state that a multidisciplinary team should carefully evaluate
patients with a BMI >35 before being included in the
waiting list (23).
A 2013 study that analyzed effectiveness of pre-transplant
weight loss in obese patients requiring LT showed that 60%
of the cohort gained weight to a BMI greater than 35 kg/m2
post-transplantation (81). Pre-transplant obesity is a
strong risk factor for developing post-transplant metabolic
syndrome. Idowu et al. stated accumulation of atherogenic
lipoproteins caused increased risk of de novo hepatic
steatosis after liver transplant (82). Kim et al. noticed
about 27.1% had NAFLD and 28.9% had severe steatosis.
Obesity at biopsy and preexisting donor graft steatosis are
important risk factors for recurrence of NASH after liver
transplant (83). Specifically, patients with a BMI greater
than 30 kg/m 2 are at greatest risk for developing posttransplant metabolic syndrome. A 2005 study by Richards
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1996–2008

58
47

Obese BMI >30
Non obese BMI <25

98

561

90

80

86

78

94

92

97

216

Non obese BMI 18–25

Patient survival (%)

3

4

85

60

89

80

94

91

80

50

80

86

82

86

75

68

68

61.3

84

86

86

78

76

78

 Length of ICU stay and wound complications are similar

 Length of surgery and transfusion requirement was same

 Intraoperative and post-operative complications are same

 Postop creatinine was higher in obese group. Operative
times, blood transfusion and ICU stay similar in both groups.
Survival was similar in both groups

 Intraoperative mortality was similar between groups

 1-, 3-, 5-year mortality was high in severely obese (BMI >40)
group compared to non-obese group

Other complications

80

88

83

78

70

70

67

71

 Primary graft dysfunction was similar in both groups

 ICU stay was similar in all groups except in class 3 obesity

 No difference in patient and graft survival

 Operative time, ICU stay, transfusions needed were higher in
obese group

 Mortality higher in obese group

 Operative time, transfusions needed, ICU stay was similar
between both groups

 No change in blood transfusions needed, post op
complications

 Morbidly obese patients had increased ICU stay

 No difference in patient and graft survival noticed

 No differences in graft survival or patient’s survival, hospital
stay, operative complications

51.3  Operative times, ICU stay, perioperative complications and
survival at 1 and 3 years similar between both groups
78.8

47

51

56

53

30-day 90-day 1 year 3-year 5-year

69

83

20

Non obese BMI 19.1c29.3
Obese BMI >30 (35-40)

20

643

Non obese BMI 18–25

Obese BMI >30

145

288

Non obese BMI <25
Obese BMI >30

167

272

Non obese BMI 18–29.9
Obese BMI >30

513

61

Non obese; mean BMI 23.4

Obese BMI >30

40

206

Non obese BMI 18.5–29.9;
mean BMI 24
Obese mean BMI 36.2

38

8,382

Non obese BMI >30
Obese BMI >30; mean BMI 34

2,611

N

Obese BMI <25

BMI (kg/m2)

1990–1994 Obese BMI >35
and 1998–2006
Non obese BMI 18.5–25

Table 3 (continued)

Mathur et al.
(69)

Leonard
et al. (68)

1997–2008

Lamattina
et al. (67)

1990–2005

Fujikawa
et al. (64)

1990–2003

2002–2012

Conzen
et al. (63)

Hilling
et al. (66)

1992–1996

Braunfeld
et al. (62)

1994–2009

1991–2006

Boin et al.
(61)

Hakeem
et al. (65)

1988–1996

Period

Nair et al.
(20)

Study name

Table 3 Previous studies that have assessed the impact of obesity on survival in post-liver transplant patients
Page 6 of 20
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2007–2009

2002–2011

2003–2013

Bhambha
et al. (76)

Beal et al.
(77)

2005–2014

Schalansky
et al. (73)

Werneck
et al. (75)

1989–1996

Sawyer
et al. (72)

1988–2011

2005–2011

Perez-Protto
et al. (71)

Singal et al.
(74)

1994–1996

Period

Nair et al.
(70)

Study name

Table 3 (continued)

17,339
34,217

Non obese BMI <30

13,262

Non obese BMI 18.5-24.9
Obese BMI >30

4062

46

Non obese BMI 18.5–24.99
Obese BMI>35

32

79

Non obese BMI 18.5–24.9
Obese BMI >30

22

969

Non obese BMI <30
Obese BMI>35

8,356

202

Non obese BMI <30
Obese BMI >35

26

183

Non obese BMI 20–26
Obese BMI >35

47

Obese BMI >38

97

96

95

94

91

92

88

88

91

75

89

96

92.2

92.5

81

77

78

94

89

64

Non obese BMI (BMI <27.3 for
men and <27.8 for women)

84.4

84.1

76

85

79

66

 Wound infections were higher in obese groups after transplant
but other long-term outcomes are similar

 Patient and graft survival similar between both groups

 Patient and graft survival similar in both groups

 ICU stay and blood transfusion needed were common
between both groups

 Post-transplant complications highest in obesity group

 Survival rate similar in all groups

 Number of blood transfusions was similar in all groups

 Length of hospital stay was higher in both obese and severely
obese patients

Other complications

89

90

 Patient mortality more in obese group

 Patient and graft survival were similar in both groups

 Patient survival and ICU stay similar between both groups

 Patient and graft survival at 1 year similar between 2 groups

78.5  Patients with obesity are at increased risk of mortality
compared to normal weight patients
78.8

30-day 90-day 1 year 3-year 5-year
90

N

Patient survival (%)

Obese BMI (>31.1 for men and 21
32.3 for women)

BMI (kg/m2)

Translational Gastroenterology and Hepatology, 2020
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et al. shows that the greatest weight gain occurs after the
first 6 months following liver transplant; dietary control
at this point is recommended to minimize long-term
morbidity and mortality resulting from obesity (84).
Diabetes mellitus
Prevalence of NAFLD is higher in patients with
diabetes (85) and is also an independent risk factor for
developing diabetes (86,87). Patients with diabetes and
NAFLD had a higher rate of hypertension, cardiovascular
disease, peripheral arterial disease, hyperlipidemia and
cerebrovascular disease, and advanced fibrosis and
also increased all-cause mortality, mortality related to
cardiovascular disease, and liver disease related mortality (88).
A recent study has also concluded that diabetes is associated
with an increased risk of HCC in patients with NASH
cirrhosis (89). A large national study has reported that
pretransplant diabetes is associated with inferior postoperative outcomes and increased resource utilization after
LT (24). Pre-transplant diabetes increased risk of portal
venous thrombosis which is an independent risk factor of
90-day post-transplant mortality (38).
Management of diabetes in a cirrhotic patient awaiting
LT is not without challenge. Diabetes is known to be
an independent risk factor for death in liver transplant
candidates (90). In cirrhotic patients, fasting glucose may
be normal in up to 23% of diabetes cases, and glycated
hemoglobin provides falsely low results, especially in
advanced cirrhosis (91,92). Similarly, the performance of
alternative glucose monitoring tests, such as fructosamine,
glycosylated albumin and 1,5-anhydroglucitol, also appears
to be suboptimal in chronic liver disease (91). There has
been a recent trend for management of these patients by
specialists (93).
In a study including 12,442 patients who underwent
LT at 63 centers from 2007–2011, pretransplant diabetes
was associated with inferior post-operative outcomes and
increased resource utilization after LT (24). Additionally,
diabetes increases the risk of developing recurrent
NASH after LT (94). Machine learning techniques have
identified diabetes among other important factors such
as recipient age, MELD score, BMI, and dialysis before
LT as the strongest predictors for 90-day postoperative
mortality (95). Type 2 diabetes, hyperlipidemia, obesity,
hypertension, insulin use seems to be important risk factors
for the development of recurrent and de novo NAFLD
(96,97). Finkenstedt et al. studied 237 transplant recipients
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and in 255 organ donors and noted that liver transplant
recipients with certain genetic characteristics like patatinlike phospholipase domain-containing protein 3 (PNPLA3)
is associated with an increased hepatic triglyceride
accumulation and recurrence of NASH (98).
The main risk factor for post-LT diabetes is the use
of immunosuppressive agents particularly the calcineurin
inhibitor (CNI) family (tacrolimus and cyclosporine) (99).
New-onset diabetes after transplant (NODAT) adversely
affects long-term survival after LT in a manner similar to
preexisting diabetes, indicating the need for more aggressive
care and closer follow-up, and possibly early post-operative
intervention. Sirolimus-based immunosuppression is
associated with a significantly higher risk of NODAT than
other immunosuppressants (100). Patients with NODAT
had reduced survival and an increased incidence of sepsis
and chronic renal insufficiency (101). Lastly, steroid free
regimens are known to decrease diabetes, hyperlipidemia,
cytomegalovirus infections but no difference in patient and
graft survival, renal insufficiency, hypertension, neurological
disorders and infectious complications were noted (102).
The importance of perioperative glucose control early
after LT must be emphasized as the association between
the immediate post-transplant glycemic control and
the development of subsequent rejection has been well
documented (103). Earlier studies have documented that
intraoperative hyperglycemia during LT was associated with
an increased risk of postoperative infection and mortality (26).
Management of blood glucose in the immediate postoperative
period with a transition from an insulin drip to a long acting
basal insulin along with prandial, rapid-acting insulin for both
diabetic and non-diabetic patients was shown to significantly
decrease infections up to 1 year from operation when
compared to standard glycemic control (104). Aside from
these well documented complications acute kidney injury
(AKI) (105) and new onset diabetes after transplantation
(NODAT) (106,107) have been associated with post-LT
variability in glucose control. These studies highlight the
importance of post-LT glycemic control to potentially
prevent graft failure and complications such as infections.
In addition, early peak NODAT has been reported in donor
grafts received after circulatory death (DCD) recipients
(within 15 days post-LT) (108). A recent meta-analysis
has concluded that hyperglycemia in the perioperative
period is associated with poor post-LT outcomes (109).
With the rising NAFLD population worldwide the need
for close monitoring of glucose levels post-LT has become
even more important as more patients with diabetes being
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transplanted. Additionally, these changes have resulted in
more donor grafts from older patients with DM and obesity
which could be more susceptible to poor outcomes from
hyperglycemic stressors (110).
Patients in the immediate perioperative period after
liver transplant are in hypercatabolic state where there is
increased tissue breakdown but not in hyper metabolic
state (111). Patients who has tendency to do uncontrolled
eating and emotional eating are at increased risk of worse
weight gain >14 kg immediately after liver transplant (112).
Post-LT patients secondary to NASH have lower resting
energy expenditure and exercise energy expenditure so they
will need aggressive diet and exercise regimens to decrease
risk of weight gain (113).
So patients are advised increased protein intake
1.3–2 g/kg body weight/day and maintain optimal
energy 25–40 kcal/kg/day. Need to continue intake of
carbohydrate—50–70% of daily calories with decreased
simple sugars and lipids 10–20% of daily calories
with increased MUFAs and PUFAs (114). Neto et al.
retrospectively reviewed patients about 5 years post liver
transplant who followed with multidisciplinary team
including nutritionist, endocrinologist working together
with surgical team after liver transplant. By adequate
control of BP, hyperlipidemia and hyperglycemia, there
was an improvement in HbA1c status and weight gain in
this study (115). Management of diabetes in liver transplant
recipients is not very different compared to pre-transplant
diabetes.
Only a few prospective studies have designed
interventions aimed at managing post-LT hyperglycemia,
post-transplant diabetes mellitus (PTDM) and their impact
on post-LT outcomes, and as such, future studies need to be
designed to address these issues.
Cardiovascular disease
The prevalence of single‐vessel and 3-vessel CAD is
significantly higher in patients with NASH cirrhosis
compared with HCV and alcoholic cirrhosis (116). Mortality
due to CAD and cerebrovascular disease is highest among
patients with NASH within first year of LT compared
to other liver disease etiologies (117). An algorithm for
guiding evaluation for LT in NASH cirrhotic patients
from a cardiovascular standpoint is summarized in Figure
1. In general considering their predisposition for CAD a
stringent cardiac evaluation is of paramount importance.
A transthoracic echocardiogram is required in all patients
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undergoing liver transplant evaluation to assess the
structural and functional capacity of the heart. If patients
have more than 2 cardiac risk factors (age >50 years,
hypertension, hyperlipidemia, obesity), stress testing
should be performed (118). Our center performs stress
testing routinely in all patients age >40 years. The two
most commonly used non-invasive stress tests are either
dobutamine stress echocardiography (DSE) or nuclear
perfusion stress testing (SPECT). Patients undergoing DSE
should discontinue any beta blocker use 48 hours prior to
the procedure as it can cause a false negative result. In our
center, the DSE is considered optimal if the LT candidate
achieves 85% of maximal heart rate. DSE is quite accurate
in diagnosing CAD in general population, but its value in
predicting CAD in cirrhotic patients with decompensated
has been suboptimal as many patients do not achieve the
maximal target heart rate. The sensitivity, specificity, PPV,
and NPV in diagnosing obstructive CAD using DSE is
13%, 85%, 22% and 75%, respectively (119). In a recent
meta-analysis, the authors found that DSE, myocardial
perfusion scintigraphy (MPS), and invasive coronary
angiography (ICA) do not satisfactorily predict increased
risk of perioperative major adverse cardiac events or allcause mortality among cirrhotic patients listed for LT,
among small and heterogenous studies, questioning the
utility of these studies (120). DSE is not recommended in
patients with a left bundle-branch block (LBBB) because
an increase in heart rate and contractility may cause septal
perfusion abnormalities (121). DSE is also contraindicated
in patients with atrial fibrillation, atrial flutter, or an
automatic implanted cardioverter defibrillator (AICD). In
patients with these conditions, nuclear perfusion testing
should be performed instead. However, recent studies
have shown that noninvasive diagnostic stress tests such as
DSE or nuclear perfusion stress test may yield nonspecific
results in patients waiting for liver transplant compared to
other patients (122). Therefore, in patients with abnormal
stress testing, coronary angiography seems to be the gold
standard. Additionally, complications from coronary
angiography and percutaneous intervention (PCI) were
low, making this a safe procedure, per a 2018 study (116).
Cardiac catheterization can be safely performed in patients
with end stage liver disease despite elevated INR and
thrombocytopenia (123). As per ACC/AHA guidelines,
coronary revascularization in candidates with severe
CAD is frequently performed prior to liver transplant
and bare metal stenting was the chosen approach. PCI
and revascularization are required in obstructive CAD
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(greater than 50% reduction in luminal diameter of major
coronaries) before a patient can be considered as a potential
transplant candidate. In liver transplant candidates requiring
bare metal stenting, LT should be delayed by a minimum
of 6 weeks (124). In patients with nonobstructive CAD,
medical management with beta blockers and statins was
suggested.
Intraoperatively, LT results in acute cardiovascular
changes, including reduced venous return and sudden
increase in peripheral vascular resistance. These are often
exacerbated by hemorrhage and reperfusion syndrome,
further compromising the already stressed hemodynamics.
Patients with end-stage liver disease (ESLD) also have
splanchnic and systemic vasodilatation secondary to
activation of the renin-angiotensin-aldosterone system.
These factors lead to increased flow both in pulmonary and
systemic circulations with the resultant elevated pressures
in the right ventricle, pulmonary artery, and left atrium in
the resting state. Additionally, cirrhotic cardiomyopathy
which is noted in 40–50% of cirrhotics, may present with
subclinical systolic and diastolic dysfunction, and can
be unmasked after LT (125). Therefore, perioperative
considerations for cardiovascular disease are significant.
As per Vanwagner et al., NASH patients were more likely
to have a cardiovascular event within 1 year after LT and
about 70% of events occurred in the perioperative period
even after controlling for recipient age, sex, smoking status,
pretransplant diabetes, cardiovascular disease, and the
presence of metabolic syndrome (13).
Predictors for post-transplant cardiovascular disease are
age, male sex, diabetes, hypertension, glomerular filtration
rate <60 mL/minute, and pre-transplant CVD (126).
Minimizing weight gain early after LT can prevent
the development of metabolic syndrome and resultant
cardiovascular disease (127). Severity or extent of CAD
does not impact post-LT survival, if appropriately
revascularized (128). Early postoperative cardiac events
are associated with inferior survival in liver transplant
recipients, irrespective of underlying CAD.
AKI
AKI is a frequent complication after LT. Thongprayoon et
al. noted an overall estimated incidence rates of post-LT
AKI and severe AKI requiring renal replacement therapy
are 40.8% and 7.0%, respectively. There are significant
associations of post-LT AKI with increased mortality and
graft failure after transplantation (30) In a study including
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1,270 patients 34% developed severe AKI, including 18%
requiring postoperative RRT. Five factors were identified as
the strongest predictors of AKI: donor and recipient BMI,
DCD grafts, fresh frozen plasma requirements, and recipient
warm ischemia time, leading to a range of 0-25 score
points with an AUC (Area under curve) of 0.70. The AKI
prediction score is a potential tool to risk stratify recipients
at risk for severe post-transplant AKI, and may be of use
in early switch to kidney-sparing immunosuppression and
early RRT (129). Even in patients with normal preoperative
renal function, AKI was a frequent complication in LT
recipients and had both negative short- or long-term effects
on patient outcomes, also the severity of AKI had a doseresponse relationship with worse outcomes. Patients with
BMI >25, prolonged inferior vena cava clamping, prolonged
cold ischemia time, or post-operative RBC requirement
>10 units should be paid particular attention, which may
assist in achieving better clinical outcomes (130). NASH
as an independent risk factor for renal dysfunction after
LT (131). Additionally, recipients with preserved renal
function before LT has shown a trend toward lower risk of
death with a functioning graft compared with spontaneous
liver and kidney transplant (SLKT) recipients and those
with pretransplant severe renal dysfunction in patients with
NASH. Renal-sparing immunosuppression regimens should
be considered at the time of LT to reduce the development
of kidney injury in NASH patients.
CKD
Prevalence of CKD ranged from 20% to 55% among
patients with NAFLD compared with 5% to 30% among
those without NAFLD (132,133). A meta-analysis showed
that increased risk of CKD persisted in NASH patients
after adjusting for diabetes (134). In patients with diabetic
kidney disease, NASH is an independent risk factor for
cardiovascular events (135), and in patients with NASH,
CKD was associated with increased overall mortality (136).
Female sex, pre-transplant CKD, and NASH are
independent predictors of development of stage 3 or greater
CKD after LT (137). Pre-transplant renal impairment
along with diabetes is a predictor for increased post-liver
transplant cardiovascular disease mortality (32).
SLKT recipients increased from 6.3% in 2002 to 19.2%
in 2011 (138). Patients with preserved renal function before
liver transplant were shown to have lower risk of death
and increased graft survival compared to those with pretransplant severe renal dysfunction in patients with NASH
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(139). Houlihan et al. noted that NASH patients undergoing
liver transplant had significantly low EGFR 3 months after
LT compared to non-NASH patients even after adjusting
for body mass index, tacrolimus levels, diabetes mellitus,
hypertension, and HCC (131). Several studies show ACE
inhibitors as a treatment for NASH and decreasing the risk
of CKD (140-142). ACE inhibitor therapy is thought to
be effective in patients with NASH by increasing insulin
sensitivity, one of the main pathogenic determinants in
NAFLD (134). Pentoxifylline has shown to improve liver
tests and also has renal protective action (143,144). Many
other drugs like fibrates, thiazolidinediones, epidermal
growth factor inhibitors, nuclear factor inhibitors are being
studied to improve inflammation and fibrosis related to
CKD in NASH patients (145). Their utility in the postLT period in NASH patients has not been well studied, but
appears to be a reasonable strategy.
Sarcopenia and functional status
Sarcopenia is the loss of skeletal mass and associated
function and is common in cirrhotic patients due to
impaired protein synthesis and inability to adequately
store glycogen. Undernutrition, sarcopenia and functional
decline increases mortality in waitlist candidate (146).
Therefore, management of sarcopenia and frailty is
essential in decreasing the dropout rate in waitlist patients.
Pretransplant sarcopenia is associated with poor shortterm survival post-living donor LT (147). Cirrhotic patients
older than 65 years are at particular risk for sarcopenia
(148,149). Sarcopenia and overall functional decline in
LT candidates on the waitlist has also been shown to be
associated with a higher risk of delisting or mortality despite
a low baseline MELD score (33). Specifically, sarcopenia
is associated with post-LT infectious complications and
sepsis-related mortality (35). Sarcopenia is diagnosed based
on low muscle mass plus either low muscle strength or low
physical performance (150). Modalities such as dual X-ray
absorptiometry, bioimpedance analysis, handgrip strength,
and gait speed have been used in diagnosis of sarcopenia.
However, measurements using dual X-ray absorptiometry
and bioimpedance analysis in cirrhotic patients specifically
may be distorted by fluid retention (151). Additionally,
diminished gait speed and handgrip strength may be due
to underlying confusion from hepatic encephalopathy and
not necessarily a result of diminished muscle mass (152).
Measurement of muscle mass by MRI or CT are gold
standards for measuring muscle mass in research (150).
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Due to multiple modalities used in diagnosing sarcopenia,
current literature yields heterogeneous results on assessment
of sarcopenia.
Physical activity should be assessed to estimate functional
capacity. Metabolic equivalent tasks (METs) are frequently
used to assess functional status because they are simple
to apply based on the ability of potential recipients to
carry out certain tasks. One MET is considered the
resting oxygen consumption of a 40-year-old 70 kg
man (153). In patients unable to perform 4 METs of
work, the preoperative risk is increased (154-156). Table 4
categorizes functional capacity based on METs. Frailty
was very prevalent in liver transplant candidates and as
frailty score increases waitlist mortality worsened (146).
Frailty usually worsens 3 months after LT so intense
exercise programs are required pre- and post-transplant to
improve endurance (157). Physical activity improves frailty
but physical activity was lower in patients awaiting liver
transplant and was known to increase portal pressure and
increase variceal bleeding (158). Also, a 12-week course of
adapted physical activity has improved muscle strength,
6-min walk distance and the ventilatory threshold power in
waitlist candidates (159). Supervised aerobic and resistance
training is shown to improve physical conditioning and
quality in post liver transplant patients (160).
Nutritional intervention should be a focus for treating
sarcopenia in cirrhotic patients awaiting LT. The European
Society for Parenteral and Enteral Nutrition (ESPEN)
recommends a target intake of 35–40 kcal/kg/day and
1.2–1.5 g/kg/day of protein (34). In patients with sarcopenia
and hepatic encephalopathy, protein restriction is not
recommended (161). In fact, protein restriction in liver
transplant candidates is associated with higher mortality
while on the waitlist (162). Due to impairments in liver
function, patients with cirrhosis have inadequate glycogen
stores. To counter the accelerated starvation state in these
patients, small, frequent meals and a late evening snack
consisting of 50 grams of complex carbohydrates are
suggested (162,163). Per a 2016 study by Sinclair et al.,
testosterone supplementation may safely increase muscle
and bone mass in cirrhotic males with sarcopenia and low
testosterone levels (164). However, there is currently no
treatment directed at cirrhotic patients with sarcopenia. A
2013 review of sarcopenia in the post-LT period attributed
unresolved sarcopenia to use of immunosuppressive
agents such as mammalian target of rapamycin (mTOR)
and CNIs, which can impair skeletal muscle growth,
repeated hospitalizations, renal impairment, and infectious
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Table 4 Metabolic equivalent tasks (METs) can be used to assess functional status in liver transplant candidates
METS

Estimated functional capacity

>10

Excellent: rope jumping, rowing, running (>7 mph)

7–10

Good: running (6 mph), circuit training

4–6

Moderate: walking up 2 flights of stairs, walking on level ground at 4 mph, cycling for leisure or commuting

<4

Poor: slow ballroom dancing, walking at 2–3 mph, light house work (cleaning, sweeping)

One MET is considered the resting oxygen consumption of a 40-year-old 70 kg man. Adapted from (118).

complications (165).
Portal venous thrombosis
Obesity and diabetes are highly prevalent in NASH
cirrhosis and are well-known risk factors for vascular
thrombosis. Additionally, obesity and diabetes are
independent risk factors for developing a pre-transplant
portal vein thrombosis (PVT) in liver transplant candidates
(166,167). According to Agbim et al., NASH transplant
recipients with PVT had a 37% increased risk of graft
failure and 31% increased risk of overall death when
compared with NASH transplant recipients without PVT at
the time of transplant. This difference in graft and patient
survival was most pronounced in the first 90 days following
LT (36).
Recent evidence suggests that NAFLD mechanistically
alters coagulation independent of abdominal adiposity and
metabolic syndrome (168). Chronic liver steatosis in NASH
patients is associated with an increase in the activity of
clotting factor VII, plasminogen activator inhibitor-1 activity
and antigen and a decrease in tissue-type plasminogen
activator (t-PA) activity (169). In patients with NASH,
factor VIII levels seem to be higher and pro C levels seem to
be lower, leading to an imbalance in coagulation status (170).
Stine et al. reviewed the data of patients who received LT
between January 01, 2003 and December 31, 2012 from
the United Network for Organ Sharing organization
and found that 6.3% patients receiving LT had PVT and
12.0% of those patients had NASH (171). Montenovo et al.
and noted that presence of portal venous thrombosis
while on the waitlist or at the time of transplant lead to
worse patient and graft survival in the post-liver transplant
period PVT was also an independent risk factor for being
removed from the waitlist (167). Martino et al. studied a
total of 465 patients and noted that waitlist mortality was
higher in patients with NASH compared to other liver
diseases but portal venous thrombosis did not affect waitlist
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mortality (37). A randomized controlled trial proved that a
12-month course of enoxaparin was effective in preventing
portal venous thrombosis in patients with cirrhosis and also
improved decompensation and survival rates (172). The
use of transjugular intrahepatic portosystemic shunt (TIPS)
may be a second-line treatment for PVT if anticoagulation
fails, however the data is scarce (173).
PVT poses a technical challenge during LT. The extent
of portal vein occlusion can lead to further problems in the
post-LT period. Restoring portal blood flow to the allograft
is essential for successful transplantation and recovery of
liver function (174,175).
Immunosuppressants
Post-transplant metabolic syndrome is very common in
NASH patients and is accentuated using immunosuppressive
agents. Optimization of dose of immunosuppressive
agents improve patient and graft survival. Steroid free
regimens are known to decrease diabetes, hyperlipidemia,
cytomegalovirus infections but no difference in patient and
graft survival, renal insufficiency, hypertension, neurological
disorders and infectious complications were noted (102).
CNI use is associated with diabetes, hypertriglyceridemia
and obesity in post-transplant patients (176). Hypertension
and hyperlipidemia are more common in patients using
cyclosporine compared to tacrolimus (177). Lower
tacrolimus trough concentrations within the first month
after LT were associated with less renal impairment at
1 year with no significant influence on acute rejection
compared to conventional tacrolimus trough levels (178).
But tacrolimus is known to increase NASH after liver
transplant (179).
Recent systematic review of 12 studies showed
prevalence of de novo NAFLD was 26% and prevalence of
NASH was 2%. Highest prevalence of de novo NAFLD
were found in patients taking tacrolimus (180). Both
cyclosporine and tacrolimus regimen use cause increased
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risk of cardiovascular events compared to non-cyclosporine
regimens (127). Post-transplant deaths, re-transplantation
rate was higher in cyclosporine group compared to
tacrolimus group (181). The utility of cyclosporine based
regimen is of historical interest only. Mycophenolate and
mammalian target of rapamycin (mTOR) inhibitors were
used to decrease the use of tacrolimus frequently in posttransplant period to decrease metabolic complications (182).
Sirolimus-based immunosuppression is associated
with a significantly higher risk of NODAT than other
immunosuppressants as noted earlier.
Conclusions
Management of NASH in the peritransplant period
possesses unique challenges to providers involved in the care
of these patients due to its associated comorbidities such as
type 2 diabetes, obesity, metabolic syndrome, cardiovascular
diseases and CKD. Optimal selection of transplant
candidates with NASH involves stringent cardiac evaluation
with low threshold for cardiac angiogram particularly in
those with high risk CAD history even in the face of normal
cardiac stress testing. Pretransplant diabetes is associated
with inferior post-operative outcomes and increased
resource utilization after LT, and as such a strict control
of diabetes using a multidisciplinary approach involving
primary care physician, endocrinologist, and dietician
combined with a structured weight loss program is of
paramount importance for obtaining an optimal outcome in
these high-risk patients. Nutritional intervention should be
a focus for treating sarcopenia in cirrhotic patients awaiting
LT with focus on high protein intake. Frailty is predictor
of poor post-transplant outcome, and supervised exercise
program should be considered in high risk patients with
poor functional capacity. Consideration should be given for
early intervention with modification of immunosuppression
regimen to protect renal function in those patients with
baseline renal dysfunction.
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